Yaron Hakak, SVP of corporate and business development at Element Biosciences, said: “Working with Revvity will allow us to greatly expand the reach of high-quality sequencing as part of a complete solution for the benefit of customers everywhere.”
Genomic data generated by next generation sequencing (NGS) plays an increasingly important role in scientific innovation and research. The NGS process encompasses a series of detailed steps, including sample collection and processing, nucleic acid extraction, library preparation, quality control, sequencing, data analysis and integration into laboratory information management systems. This process can be daunting, especially for labs that are new to NGS and are considering routine use of genomic sequencing data. This data is crucial to driving research into human health improvements as reflected in research publications and ongoing studies in many disease identification efforts, including neonatal research applications.
Revvity offers carefully curated research use components, spanning the NGS continuum around the sequencing platform. These offerings include sample collection devices, a DBS puncher for punching dried blood spot samples, chemagic kits and instruments for automated nucleic acid extraction, a wide range of liquid handlers and reagent kits for automated library preparation, the LabChip GX Touch HT nucleic acid analyzer and VICTOR2 D Instrument for sample quality control, and software capabilities that are vital for data management and interpretation. For labs interested in a service model, Revvity Omics provides end-to-end solutions from delivery of a sample collection kit to final report, providing the flexibility to access sequence data only or report only to augment the customer’s in-house capabilities.
When it comes to the NGS platform itself, data quality and flexibility play a pivotal role in determining a lab’s choice for advancing research. The Element AVITI System, a flexible benchtop sequencer with industry-leading performance and cost, delivers high quality, affordable data for any application, at a range of scale. Element’s AVITI System is quickly gaining broader adoption, exceeding 100 commercial orders from customers
across the globe. Earlier this year, Element Biosciences announced a new throughput-based option for its AVITI System that provides the highest quality sequencing on a benchtop for as low as $200 a genome, or $2 per gigabase. Revvity Omics has recently adopted Element’s AVITI platform for its global service business, demonstrating improved technology capabilities, flexibility and speed.
Revvity and Element Biosciences plan to make the combined solution available to an expanded customer base interested in the full workflow or specific modules.
• Laboratories interested in discussing their research needs can do so via this dedicated channel: https://info.revvity.com/ngs-element-biosciences